Apeloa Pharmaceutical Co., Ltd.
Research Apeloa Pharmaceutical Co., Ltd. (000739.SZ) on Bullrun: market cap CNY 27.13B, P/E 31.6, dividend yield 1.6%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker000739.SZ
- ExchangeSZ
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyCNY
- Market capCNY 27.13B
- P/E31.6
- Dividend yield1.6%
- Financial periodQ2 2026
- RevenueCNY 2.38B
- Net incomeCNY 273.35M
- Free cash flow-CNY 170.27M
- Gross margin29.8%
Valuation Snapshot
latest market cap is CNY 27.13B; P/E is 31.6; dividend yield is 1.6%.
Peer valuation comparison
Latest P/E is 31.65x versus a Healthcare sector median of 21.75x (45.5% above).
Latest dividend yield is 1.61% versus a Healthcare sector median of 2.4% (32.9% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | CNY 27.13B | 31.6 | 1.6% | 0.38 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.38 CNY, yield 1.6%.
About Apeloa Pharmaceutical Co., Ltd.
Apeloa Pharmaceutical Co.,Ltd provides raw materials various pharmaceutical factories in the People's Republic of China and internationally. The company operates through API, CDMO, and Pharmaceutical segments. It offers API intermediates business, which includes cephalosporin, penicillin, psychotropic, cardiovascular and cerebrovascular, and veterinary API intermediates series;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Apeloa Pharmaceutical Co., Ltd.'s market cap?
Apeloa Pharmaceutical Co., Ltd.'s market capitalization is CNY 27.13B.
What is Apeloa Pharmaceutical Co., Ltd.'s P/E ratio?
Apeloa Pharmaceutical Co., Ltd.'s price-to-earnings (P/E) ratio is 31.6.
Does Apeloa Pharmaceutical Co., Ltd. pay a dividend?
Apeloa Pharmaceutical Co., Ltd. has a dividend yield of 1.6%.
What does Apeloa Pharmaceutical Co., Ltd. do?
Apeloa Pharmaceutical Co.,Ltd provides raw materials various pharmaceutical factories in the People's Republic of China and internationally. The company operates through API, CDMO, and Pharmaceutical segments.